Reading Time: 2 minutes
Genmab (i.) specializes in monoclonal antibodies for oncological therapy. The current growth driver in the portfolio is the drug EPKINLY, which is used for the treatment of blood cancer. Sales of EPKINLY have increased by 48% in the first half of the year. The growth could continue as bispecific antibodies can be used more precisely than classical chemotherapy. This allows many healthy body cells to be spared. Although there are side effects, the market is seeking such more targeted therapeutic solutions. The fact that management was able to present...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
